Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Confirmed HER2-positive breast cancer that cannot be surgically removed or has spread
- Either no prior chemotherapy for advanced disease, OR previously treated with taxane and trastuzumab drugs
- Your doctor plans to start you on pyrotinib as your next treatment
- Your medical records from throughout your treatment must be available
- Not currently enrolled in another clinical trial testing investigational drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This trial tests a sequence of targeted therapy drugs for HER2-positive advanced breast cancer that has spread or cannot be removed by surgery. It aims to see if starting with trastuzumab rezetecan, followed by pyrotinib and trastuzumab plus capecitabine, helps control the cancer.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This study tests a targeted therapy called pyrotinib for people with advanced or metastatic HER2-positive breast cancer. It aims to see how well the drug works in a real-world setting, helping guide treatment for this specific type of cancer.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.